Abstracts tagged "Fracture risk"

Abstract Number: 2542 • 2016 ACR/ARHP Annual Meeting
Reducing the Dosage of Glucocorticoid to Zero Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
Kenji Mamoto¹, Kentaro Inui², Tadashi Okano¹, Yuko Sugioka³, Masahiro Tada⁴, Tatsuya Koike⁵ and Hiroaki Nakamura⁶, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatology & Orthopaedics, Higashisumiyoshi Morimoto Hospital, Osaka, Japan, ³o, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan, ⁵Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ⁶Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falls and fractures. The…
Abstract Number: 327 • 2016 ACR/ARHP Annual Meeting
Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis
Ji-Heh Park¹, Seung-Geun Lee¹, Eun-Kyoung Park², Hee-Sang Tag³ and Geun-Tae Kim⁴, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ⁴Kosin University College of Medicine, Busan, South Korea
Background/Purpose: As rheumatoid arthritis (RA) is a well-established risk factor for osteoporosis and compression fracture, non-adherence to bisphosphonate (BP) therapy in patients with RA can…
Abstract Number: 331 • 2016 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Takefumi Furuya¹, Eisuke Inoue^1,2, Masanori Nakayama¹, Eiichi Tanaka¹, Katsunori Ikari¹, Ayako Nakajima³, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Previous U.S. and Canadian studies [1-3] have suggested that no significant associations exist between use of biologic disease-modifying anti-rheumatic drugs (DMARDs) and risk of…
Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting
Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study
Sarah Dyball¹ and Marwan Bukhari², ¹University Hospital South Manchester, Manchester, United Kingdom, ²Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…
Abstract Number: 228 • 2015 ACR/ARHP Annual Meeting
Gout and Risk of Non-Vertebral Osteoporotic Fracture
Seoyoung C. Kim¹, Julie M. Paik², Jun Liu³, Gary C. Curhan² and Daniel H. Solomon⁴, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Renal Division, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest an association between osteoporosis, systemic inflammation and pro-inflammatory cytokines such as IL-1 and IL-6. Gout is a common inflammatory arthritis characterized…
Abstract Number: 353 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Cohort Study of Weekly Teriparatide, Denosmab, and Bisphosphonates for Prevention of Vertebral Fractures in Glucocorticoid-Induced Osteoporosis
Hisaji Oshima¹, Mari Ushikubo¹, Kumiko Akiya¹, Ikuko Tanaka², Shigenori Tamaki² and Keisuke Izumi³, ¹Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ²NAGOYA Rheumatology Clinic, Nagoya, Japan, ³National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: Although weekly teriparatide (56.5ug, wTPTD) and denosmab (DMAB) have been developed as potent anti-osteoporotic agents, effects of these agents on prevention of osteoporotic fractures…
Abstract Number: 364 • 2015 ACR/ARHP Annual Meeting
Very High Frequency of Fragility Fractures Associated with High-Dose Glucocorticoids in Postmenopausal Women: A Retrospective Study
Goichi Kageyama¹, Takaichi Okano¹, Yuzuru Yamamoto¹, Keisuke Nishimura¹, Daisuke Sugiyama², Jun Saegusa¹, Goh Tsuji³, Shunichi Kumagai⁴ and Akio Morinobu¹, ¹Department of Rheumatology, Kobe University Hospital, Kobe, Japan, ²Department of Preventive Medicine and Public Health, Keio University, Tokyo, Japan, ³The Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, ⁴The Center of Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: To evaluate the incidence of fragility fractures associated with high-dose glucocorticoid therapy in patients with systemic rheumatic disease.Methods: A retrospective study of patients who were treated with high-dose…
Abstract Number: 369 • 2015 ACR/ARHP Annual Meeting
Incidence of Fragility Hip Fractures over 10 Years (2004-13) in Three UK Centres with Reference to Local Fracture Prevention (‘fracture liaison’) Service Activity
Gavin Clunie¹ and Jonathan Belsey², ¹Rheumatology, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom, ²JB Medical, Sudbury, United Kingdom
Background/Purpose: Fracture Liaison Services systematically identify patients with fragility fracture and screen patients for osteoporosis and associated conditions and instigate evidence-based 'secondary' fracture prevention management.…
Abstract Number: 373 • 2015 ACR/ARHP Annual Meeting
Compared to Non-Users, Current Glucocorticoids Users Have Less Prevalent Fractures at the Same Bone Mass: Results of a Large Cross-Sectional Study
Marwan Bukhari¹, Nicola Goodson^2,3 and Maarten Boers⁴, ¹Rheumatology, Royal Lancaster Infirmary, Consultant and Honorary Senior Lecturer, Lancaster, United Kingdom, ²Rheumatology, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, University Hospital Aintree, Liverpool, United Kingdom, ⁴Amsterdam Rheumatology and Immunology Center, VU University Medical center, Amsterdam, Netherlands
Background/Purpose: It is widely believed that use of glucocorticoids (GC) increase risk of fracture through reduction in bone quality as well as reduction in bone…
Abstract Number: 378 • 2015 ACR/ARHP Annual Meeting
Osteoporotic Fragility Tibia/Fibula Fractures Are Not Asociated with a Low Body Mass Index: An Observational Study
Vishnu Kammath¹ and Marwan Bukhari², ¹Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom, ²Rheumatology, Royal Lancaster Infirmary, Consultant and Honorary Senior Lecturer, Lancaster, United Kingdom
Background/Purpose: Tibia/Fibula (Tib/Fib) fractures are one of osteoporotic fragility fractures. They have been suggested to be more likely to occur secondary to osteoporosis (OP) than…
Abstract Number: 2233 • 2015 ACR/ARHP Annual Meeting
Predictors of Imminent Fracture Risk in Women Aged >=65 Years with Osteoporosis
Derek Weycker¹, Richard Barron², Alex Kartashov¹, John Edelsberg¹, DB Crittenden³ and A Grauer³, ¹Policy Analysis Inc. (PAI), Brookline, MA, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Fractures are the major source of morbidity among women with osteoporosis. However, evidence on factors leading to imminent risk for hip or other non-vertebral…
Abstract Number: 2047 • 2014 ACR/ARHP Annual Meeting
No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort
Shivani Sahni¹, Kelsey Mangano², Katherine Tucker³, Caroline Fox⁴, Douglas P. Kiel⁵, Xiaochun Zhang⁶ and Marian T. Hannan¹, ¹Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Clinical Laboratory & Nutritional Sciences, Center for Population Health & Health Disparities, University of Massachusetts, Lowell, MA, ⁴Institute of Genetics and Biophysics, NHLBI's Framingham Heart Study and Center for Population Studies, Framingham, MA, ⁵Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA
Background/Purpose: Serum uric acid (UA) has been linked with fractures in older men. Three different studies in older men showed conflicting results. The objective…
Abstract Number: 2004 • 2014 ACR/ARHP Annual Meeting
Osteoporosis Screening and Fracture Risk Assessment Tool Usage Among House Staff
Jordan Brodsky¹, Meghan Greenfield² and Erin Patton³, ¹Medicine, Albert Einstein College of Medicine, Woodmere, NY, ²279 E 10th St, Beth Israel Medical Center, New York, NY, ³Rheumatology, Beth Israel Medical Center, New York, NY
Background/Purpose: Despite increased awareness of the magnitude and consequences of osteoporosis and the availability of recommendations for screening and treatment by multiple organizations, osteoporosis is…
Abstract Number: 919 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65
Akhila Balasubramanian¹, Sally Wade², Robert A Adler³, Celia Fang (Lin)⁴, Michael Maricic⁵, Cynthia O'Malley¹, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Wade Outcomes Research and Consulting, Salt Lake City, UT, ³Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, ⁴Amgen, Thousand Oaks, CA, ⁵Catalina Pointe Rheumatology, Tucson, AZ, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Systemic glucocorticoid use can increase fracture risk, although dose-specific effects are not well understood, especially in younger adults. Underlying diseases (e.g., rheumatoid arthritis [RA])…
Abstract Number: 239 • 2014 ACR/ARHP Annual Meeting
Does Adjusting BMI for Lean Mass Deficits Affect Calculated Fracture Risk Using FRAX in Rheumatoid Arthritis?
Brittany Adler¹ and Joshua F. Baker², ¹Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA
Background/Purpose Osteoporotic fractures are a cause of morbidity in rheumatoid arthritis (RA) and low body mass index (BMI) is a risk factor for osteoporotic fractures…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.